** Hong Kong-listed shares of RemeGen Co 9995.HK rise 5.3% to HK$84.65, their highest point since December 2021, and on course for second session of gains
** Shanghai-listed stock 688331.SS climbs 5.6% to 83.93 yuan, their highest level since February 2023
** RemeGen says it has granted Santen Pharmaceutical Co's 4536.T unit Santen Pharmaceutical (China) the exclusive rights to develop, manufacture and commercialize the company's RC28-E Injection in Greater China, South Korea, Thailand, Vietnam, Singapore, the Philippines, Indonesia and Malaysia
** Company shall receive from Santen China an upfront payment of 250 million yuan ($34.79 million), development and regulatory milestone payments of up to 520 million yuan, and sales milestone payments of up to 525 million yuan
** RemeGen says it will also receive tiered sales royalties ranging from high single-digit to double-digit percentages based on product sales within the licensed territories
** RemeGen's developed RC28-E Injection is a drug for ocular neovascular diseases
** YTD, Hong Kong stock up 483.3%, Shanghai shares up 172.7%
($1 = 7.1858 Chinese yuan)
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。